Recon: Novartis loses patent appeal for MS drug Gilenya; European Commission investigates Vifor for anticompetitive practices

Recon

ReconMichael Mezher

Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy